Skip to main
VCYT

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Veracyte Inc reported a strong financial performance with a non-GAAP operating margin of 28.8%, reflecting an increase of 830 basis points year-over-year, alongside an adjusted EBITDA margin of 30.1%, which was up 650 basis points year-over-year. The company experienced robust growth in genomic test volume, achieving approximately 45,888 tests, a growth rate of 18%, with notable contributions from Decipher prostate tests and Afirma thyroid tests, which both set new records. Additionally, Veracyte's management increased the adjusted EBITDA margin guidance for 2025 to approximately 25.0%, a significant improvement over the previous year's performance, indicating a positive trajectory for profitability moving forward.

Bears say

Veracyte faces significant risks related to weaker-than-expected sales from its Decipher and Afirma tests, which could adversely impact its operating margins and free cash flow. Recent financial metrics show a decline in revenue per test and a projected decrease in adjusted EBITDA margins for 2026, indicating potential challenges in profitability. Additionally, while test volume growth remains positive, it has slowed compared to previous periods, suggesting a risk to sustained revenue growth, compounded by the concern of overall market performance falling short of expectations.

Veracyte (VCYT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 7 analysts, Veracyte (VCYT) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.